Skip to Main Content

Author Details

David A Largaespada
University of Minnesota
1990
234
60
PMIDPaper TitleJournal TitlePublished Year
38042450Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership.Int J Radiat Oncol Biol Phys2024
38042450Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership.Int J Radiat Oncol Biol Phys2024
36778419CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.bioRxiv2023
37848948Perinatal folate levels do not influence tumor latency or multiplicity in a model of NF1 associated plexiform-like neurofibromas.BMC Res Notes2023
38000020CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.Sci Adv2023
36778419CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.bioRxiv2023
36959711Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line models.Genes Chromosomes Cancer2023
37330719Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.J Invest Dermatol2023
37264057Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell-cell interactions.Commun Biol2023
37318402Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.J Invest Dermatol2023
37246765Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.Neuro Oncol2023
37117218RAD-TGTs: high-throughput measurement of cellular mechanotype via rupture and delivery of DNA tension probes.Nat Commun2023
37298259DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.Int J Mol Sci2023
37164978Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.Nat Commun2023
37520682Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.Mol Ther Nucleic Acids2023
37035203Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors.Front Oncol2023
37520682Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.Mol Ther Nucleic Acids2023
38000020CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.Sci Adv2023
37848948Perinatal folate levels do not influence tumor latency or multiplicity in a model of NF1 associated plexiform-like neurofibromas.BMC Res Notes2023
37318402Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.J Invest Dermatol2023
37117218RAD-TGTs: high-throughput measurement of cellular mechanotype via rupture and delivery of DNA tension probes.Nat Commun2023
37246765Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.Neuro Oncol2023
37035203Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors.Front Oncol2023
37298259DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.Int J Mol Sci2023
37330719Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.J Invest Dermatol2023
37164978Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.Nat Commun2023
37264057Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell-cell interactions.Commun Biol2023
36959711Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line models.Genes Chromosomes Cancer2023
35876221Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.ACS Nano2022
35972367Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.CRISPR J2022
36358254Identification of <i>NRAS</i> Downstream Genes with CRISPR Activation Screening.Biology (Basel)2022
35900472Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line.Mol Cancer Res2022
35876221Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.ACS Nano2022
35687718In Vitro Insertional Mutagenesis Screen Identifies Novel Genes Driving Breast Cancer Metastasis.Mol Cancer Res2022
35687718In Vitro Insertional Mutagenesis Screen Identifies Novel Genes Driving Breast Cancer Metastasis.Mol Cancer Res2022
35972367Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.CRISPR J2022
35900472Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line.Mol Cancer Res2022
36358254Identification of <i>NRAS</i> Downstream Genes with CRISPR Activation Screening.Biology (Basel)2022
33320737R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers.DNA Cell Biol2021
34079083WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.Oncogene2021
33808166Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development.Cancers (Basel)2021
33669386Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.Int J Mol Sci2021
33941535Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling.Cancer Immunol Res2021
33661977Flow Assisted Mutation Enrichment (FAME): A highly efficacious and efficient method to enrich Double Knockouts (DKO) after gene editing.PLoS One2021
33721151Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.Curr Oncol Rep2021
33978635Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.Neurooncol Adv2021
33025139Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.Acta Neuropathol2021
33112994Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.Acta Neuropathol2021
33407928Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma.Biol Sex Differ2021
33320737R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers.DNA Cell Biol2021
  • 1 - 50 of 468

Recommended Authors

Rahul K Kollipara
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 0
Shondra M Pruett-Miller
St. Jude Children's Research Hospital.
Career Start Year 2006
Number of shared co-authors 5
Kosuke Yusa
Wellcome Sanger Institute
Career Start Year 2003
Number of shared co-authors 5
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Monte M Winslow
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 0
Wendy Dubois
Center for Cancer Research, National Cancer Institute
Career Start Year 2000
Number of shared co-authors 3
Sandra Burkett
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 7
Kevin S Smith
Stanford University
Career Start Year 1997
Number of shared co-authors 0
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 5
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 11
Karlyne M Reilly
Center for Cancer Research, National Cancer Institute
Career Start Year 1996
Number of shared co-authors 16
Agnes Viale
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 9
Neal C Goodwin
Career Start Year 1992
Number of shared co-authors 4
Benjamin S Braun
Benioff Children's Hospitals, University of California san francisco
Career Start Year 1992
Number of shared co-authors 5
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 26
James DeGregori
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 0
Glenn S Cowley
Broad Institute of Harvard and MIT
Career Start Year 1990
Number of shared co-authors 2
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 16
Geoffrey Neale
St. Jude Children's Research Hospital
Career Start Year 1989
Number of shared co-authors 32
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 11
Frank Buchholz
University Hospital Carl Gustav Carus, Technische Universitat (TU) Dresden
Career Start Year 1989
Number of shared co-authors 6
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 17
Monica J Justice
The Hospital for Sick Children
Career Start Year 1986
Number of shared co-authors 4
William C Skarnes
Wellcome Trust Sanger Institute
Career Start Year 1986
Number of shared co-authors 4
Nathalie Conte
The Wellcome Trust Sanger Institute
Career Start Year 1983
Number of shared co-authors 6
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 7
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 15
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1978
Number of shared co-authors 15
Allan Bradley
The Wellcome Trust Sanger Institute
Career Start Year 1966
Number of shared co-authors 10

Collaborators

Branden S Moriarity
University of Minnesota
Co-authored papers 38
Kevin A T Silverstein
Minnesota Supercomputing Institute, University of Minnesota
Co-authored papers 11
Natalie K Wolf
Masonic Cancer Center, University of Minnesota
Co-authored papers 9
Aron M Geurts
Co-authored papers 9
John D Shaughnessy
Co-authored papers 8
Rebecca S LaRue
Minnesota Supercomputing Institute, University of Minnesota
Co-authored papers 8
Logan G Spector
Division of Epidemiology and Clinical Research, University of Minnesota
Co-authored papers 7
Keiko Akagi
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Stephen C Ekker
Co-authored papers 6
David J Adams
Wellcome Sanger Institute
Co-authored papers 6
George M Otto
University of California berkeley
Co-authored papers 6
Takuro Nakamura
Tohoku University Graduate School of Medicine
Co-authored papers 5
Anat Stemmer-Rachamimov
Massachusetts General Hospital
Co-authored papers 5
Margaret R Wallace
UF Genetics Institute, University of Florida
Co-authored papers 5
Colin F Fletcher
Co-authored papers 5
Jon D Larson
NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 5
William A Weiss
University of California san francisco
Co-authored papers 4
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 4
Madison T Weg
Masonic Cancer Center, University of Minnesota
Co-authored papers 4
Todd E Scheetz
the University of Iowa Carver College of Medicine
Co-authored papers 4
Jaishri O Blakeley
Johns Hopkins University
Co-authored papers 4
Kelsie L Becklin
University of Minnesota
Co-authored papers 4
Andrey Korshunov
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 3
Gerrit A Meijer
The Netherlands Cancer Institute
Co-authored papers 3
Angela C Hirbe
Washington University School of Medicine and Siteman Cancer Center
Co-authored papers 3
Kenneth Aldape
National Cancer Institute
Co-authored papers 3
Fausto J Rodriguez
University of California Los Angeles
Co-authored papers 3
Stefan M Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 3
Sara J C Gosline
Pacific Northwest National Laboratory (PNNL)
Co-authored papers 3
Release 1.2